IMNM vs. CRNX, ZLAB, MTSR, DNLI, XENE, MOR, TWST, VCEL, CPRX, and MLTX
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Metsera (MTSR), Denali Therapeutics (DNLI), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.
Immunome vs.
Immunome (NASDAQ:IMNM) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking.
Crinetics Pharmaceuticals has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. Crinetics Pharmaceuticals' return on equity of -36.12% beat Immunome's return on equity.
Immunome currently has a consensus target price of $28.60, indicating a potential upside of 200.07%. Crinetics Pharmaceuticals has a consensus target price of $72.64, indicating a potential upside of 93.82%. Given Immunome's stronger consensus rating and higher probable upside, research analysts plainly believe Immunome is more favorable than Crinetics Pharmaceuticals.
44.6% of Immunome shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 8.6% of Immunome shares are held by insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than Immunome. MarketBeat recorded 3 mentions for Crinetics Pharmaceuticals and 1 mentions for Immunome. Immunome's average media sentiment score of 1.82 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Immunome is being referred to more favorably in the media.
Immunome has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Immunome has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
Crinetics Pharmaceuticals received 126 more outperform votes than Immunome when rated by MarketBeat users. However, 74.42% of users gave Immunome an outperform vote while only 69.30% of users gave Crinetics Pharmaceuticals an outperform vote.
Summary
Immunome and Crinetics Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
This page (NASDAQ:IMNM) was last updated on 2/22/2025 by MarketBeat.com Staff
